- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GPOs respond to new market
Group purchasing organizations grew in numbers, consolidated and expanded services last year, according to SMG, a Chicago-based market research and consulting firm.
Group purchasing organizations grew in numbers, consolidated and expanded services last year, according to SMG, a Chicago-based market research and consulting firm.
SMG data reveals that the total number of multihospital systems and GPOs grew from 582 in 1995 to 720 in 1996.
The 20 largest "super groups" claim access to 87% of all U.S. hospitals and staffed beds - 96% of all acute care hospitals and beds. These groups offer high purchasing volumes and compliance to health care product manufacturers and distributors in exchange for contracted discounts, value-added services and other improved contract terms. In addition to the super-group mergers, smaller regional alliances are jumping on the bandwagon and actively joining with some of the national groups.
SMG said 420 groups have contracts with alternate health care sites, a 16% increase from the previous year. In addition to the increased contracts with surgery centers, health maintenance organizations and other sites, contracts for capital equipment, consulting services and equipment services are becoming increasingly common. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
